Roche Licenses Parkinson's Therapy From Alector For Up To $1.27B
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental Parkinson's disease treatment. Alector will receive $100 million upfront and potential future payments.
27 billion to license Alector's experimental Parkinson's disease treatment, the US biotech said on Monday, sending its shares up 72% in premarket trading. 27 billion in total under the deal.